$AADI
Aadi Bioscience, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020052756 Filed on November 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $231.0K $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $500.0K $2.160M $2.800M
YoY Change -76.85% -34.15% -10.83%
% of Gross Profit
Research & Development $2.400M $2.845M $2.264M
YoY Change -15.63% -34.55% -46.46%
% of Gross Profit
Depreciation & Amortization -$23.17K $20.00K $20.00K
YoY Change -215.85% 0.0% 100.0%
% of Gross Profit
Operating Expenses $2.894M $4.967M $5.979M
YoY Change -41.73% -34.85% -18.87%
Operating Profit -$2.663M -$4.967M -$5.979M
YoY Change -46.38% -144.35% -0.95%
Interest Expense $229.0K $239.4K $290.4K
YoY Change -4.35% -28.12% 524.95%
% of Operating Profit
Other Income/Expense, Net -$228.0K $318.7K $295.3K
YoY Change -171.54% -6.11% 535.55%
Pretax Income -$2.891M -$4.650M -$5.680M
YoY Change -37.83% -140.29% -5.18%
Income Tax $1.000K
% Of Pretax Income
Net Earnings -$2.892M -$4.648M -$5.684M
YoY Change -37.78% -140.29% -5.11%
Net Earnings / Revenue -1251.95%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.14 -$1.72 -$2.10
COMMON SHARES
Basic Shares Outstanding 40.59M
Diluted Shares Outstanding 40.59M

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $47.28M $43.40M $48.20M
YoY Change 8.94% -36.92% -29.94%
Cash & Equivalents $7.730M $43.39M $48.16M
Short-Term Investments
Other Short-Term Assets $2.301M $876.5K $264.3K
YoY Change 162.56% -26.96% 23.82%
Inventory
Prepaid Expenses $538.3K $368.0K
Receivables
Other Receivables
Total Short-Term Assets $49.58M $44.80M $48.79M
YoY Change 10.67% -35.99% -29.72%
LONG-TERM ASSETS
Property, Plant & Equipment $227.1K $281.7K $297.6K
YoY Change -19.39% 181.71% 223.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.00K $0.00 $0.00
YoY Change
Total Long-Term Assets $247.1K $747.4K $810.7K
YoY Change -66.94% 273.71% 617.34%
TOTAL ASSETS
Total Short-Term Assets $49.58M $44.80M $48.79M
Total Long-Term Assets $247.1K $747.4K $810.7K
Total Assets $49.83M $45.55M $49.60M
YoY Change 9.39% -35.11% -28.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $709.3K $751.0K $511.2K
YoY Change -5.56% 4.74% -52.38%
Accrued Expenses $1.803M $2.900M $3.100M
YoY Change -37.84% 0.0% 63.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.512M $3.601M $3.596M
YoY Change -30.25% -1.19% -83.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $200.0K $300.0K
YoY Change
Total Long-Term Liabilities $0.00 $200.0K $300.0K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.512M $3.601M $3.596M
Total Long-Term Liabilities $0.00 $200.0K $300.0K
Total Liabilities $2.512M $3.837M $3.884M
YoY Change -34.54% 6.59% -82.02%
SHAREHOLDERS EQUITY
Retained Earnings -$137.8M -$133.1M
YoY Change 24.76% 9.15%
Common Stock $179.5M $178.9M
YoY Change 1.44% 5.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$20.49M $41.71M $45.72M
YoY Change
Total Liabilities & Shareholders Equity $49.83M $45.55M $49.60M
YoY Change 9.39% -35.08% -28.67%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$2.892M -$4.648M -$5.684M
YoY Change -37.78% -140.29% -5.11%
Depreciation, Depletion And Amortization -$23.17K $20.00K $20.00K
YoY Change -215.85% 0.0% 100.0%
Cash From Operating Activities -$15.78M -$4.770M -$5.140M
YoY Change 230.77% -23.31% -139.21%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $120.0K
YoY Change -50.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $12.20K -$10.00K -$120.0K
YoY Change -222.0% -50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.194M 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -15.78M -4.770M -5.140M
Cash From Investing Activities 12.20K -10.00K -120.0K
Cash From Financing Activities 1.194M 0.000 0.000
Net Change In Cash -14.57M -4.780M -5.260M
YoY Change 204.85% -16033.33% -109.56%
FREE CASH FLOW
Cash From Operating Activities -$15.78M -$4.770M -$5.140M
Capital Expenditures $10.00K $120.0K
Free Cash Flow -$4.780M -$5.260M
YoY Change -23.4% -140.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
arpo:LicenseRevenueMember
CY2019Q3 us-gaap Restructuring Costs
RestructuringCosts
-38810
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15000000
us-gaap Restructuring Costs
RestructuringCosts
876284
CY2020Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
897378
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
897378
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
9276032
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
42600459
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9340842
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
332141
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
58666575
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
621685
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-8492825
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
50795435
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19025
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-236953
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9743637
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
604661
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-5683616
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
45716480
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
645899
us-gaap Depreciation
Depreciation
45887
us-gaap Share Based Compensation
ShareBasedCompensation
967949
us-gaap Share Based Compensation
ShareBasedCompensation
1872245
arpo Increase Decrease In Prepaid Research And Development Contracts
IncreaseDecreaseInPrepaidResearchAndDevelopmentContracts
144701
arpo Increase Decrease In Prepaid Research And Development Contracts
IncreaseDecreaseInPrepaidResearchAndDevelopmentContracts
-216092
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1090666
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
260811
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-564367
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18987454
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19025
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38524536
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
62614010
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
41714449
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
402795
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9340842
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8757450
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-19224407
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47281986
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43389603
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
402795
us-gaap Profit Loss
ProfitLoss
402346
us-gaap Profit Loss
ProfitLoss
-18824371
us-gaap Depreciation
Depreciation
53692
arpo Consulting Expenses Related To Warrant
ConsultingExpensesRelatedToWarrant
71939
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-817121
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-2044301
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
236953
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: prepaid and accrued research and development expense, stock-based compensation expense, revenue recognition and income taxes. </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s results can also be affected by economic conditions, global health concerns, such as COVID-19, and political, legislative, regulatory and legal actions. Economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, government fiscal policies, and changes in the prices of research studies, can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities and carries various levels of insurance, the Company could be affected by civil, criminal, regulatory or administrative actions, claims or proceedings.</p>
us-gaap Intangible Assets Finite Lived Policy Costs Incurred To Renew Or Extend
IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patents </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in connection with the application for and issuances of patents are expensed as incurred. </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-Balance Sheet Risk </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents are the only financial instruments that potentially subject the Company to concentrations of credit risk. At September&#160;30, 2020 and December&#160;31, 2019, the Company maintains its cash and cash equivalents with high-quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements. </p>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6936
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6583
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2020Q2 us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
15000000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2019Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2020Q3 arpo Accrued Project Costs Current
AccruedProjectCostsCurrent
850330
CY2019Q4 arpo Accrued Project Costs Current
AccruedProjectCostsCurrent
382131
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
709272
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
439785
CY2020Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
480324
CY2019Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
689830
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
234151
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
346999
CY2020Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
83402
CY2019Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
43470
CY2020Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
38114
CY2019Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
793913
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
21579
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13463
CY2019Q4 arpo Accrued Retention Bonus Current
AccruedRetentionBonusCurrent
521859
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
600000
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
917562
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
600000
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
317562
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.486
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.00
CY2019 arpo Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P3Y
CY2019Q4 arpo Warrants Vesting Period
WarrantsVestingPeriod
P6M
arpo Class Of Warrant Or Right Expiration Date
ClassOfWarrantOrRightExpirationDate
2024-10-24
CY2019 arpo Class Of Warrant Or Right Expiration Date
ClassOfWarrantOrRightExpirationDate
2020-03-15
CY2020Q1 arpo Number Of Class Of Warrants Expired
NumberOfClassOfWarrantsExpired
317562
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0232
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
962720
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.71
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1776807
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
332141
CY2019Q3 us-gaap Share Based Compensation
ShareBasedCompensation
645899
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.43
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.43
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.11
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M1D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M7D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0053
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2019Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2019Q4 arpo Penalties On Termination Of Lease
PenaltiesOnTerminationOfLease
0
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
28357
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
62086
us-gaap Operating Lease Cost
OperatingLeaseCost
85072
us-gaap Operating Lease Cost
OperatingLeaseCost
186226
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
29625
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
62634
us-gaap Operating Lease Payments
OperatingLeasePayments
87915
us-gaap Operating Lease Payments
OperatingLeasePayments
186942
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9M29D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1328
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
29865
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
69685
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
99550
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4763
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
94787
CY2020Q2 us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
15000000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
arpo Maximum Amount Of Milestone Payments Eligible To Receive Under License Agreement
MaximumAmountOfMilestonePaymentsEligibleToReceiveUnderLicenseAgreement
40000000
arpo Maximum Amount Of Sales Milestone Payments Eligible To Receive Under License Agreement
MaximumAmountOfSalesMilestonePaymentsEligibleToReceiveUnderLicenseAgreement
50000000
arpo Percentage Of Payments Received By Licensee
PercentageOfPaymentsReceivedByLicensee
0.20

Files In Submission

Name View Source Status
0001564590-20-052756-index-headers.html Edgar Link pending
0001564590-20-052756-index.html Edgar Link pending
0001564590-20-052756.txt Edgar Link pending
0001564590-20-052756-xbrl.zip Edgar Link pending
arpo-10q_20200930.htm Edgar Link pending
arpo-20200930.xml Edgar Link completed
arpo-20200930.xsd Edgar Link pending
arpo-20200930_cal.xml Edgar Link unprocessable
arpo-20200930_def.xml Edgar Link unprocessable
arpo-20200930_lab.xml Edgar Link unprocessable
arpo-20200930_pre.xml Edgar Link unprocessable
arpo-ex311_8.htm Edgar Link pending
arpo-ex312_9.htm Edgar Link pending
arpo-ex321_7.htm Edgar Link pending
arpo-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending